This work represents the first report of a bioengineered version of CD19-L, a recombinant human biotherapeutic agent, targeting CD19-positive leukemic stem cells.
本研究工作为CD19-L的生物工程版本（一种重组的人类生物治疗因子，其靶标为CD19阳性白血病干细胞）的首篇报告。
Are Leukemic Patient Bone Marrow Mesenchymal Stem Cells Malignant?
骨髓间充质干细胞是否是恶性细胞？
Are Leukemic Patient Bone Marrow Mesenchymal Stem Cells Malignant?
骨髓间充质干细胞是否是恶性细胞？
应用推荐